Unnamed: 0,title,date,stock,sentiment
328132.0,Cyclacel Pharmaceuticals Announces First Patient Treated In Phase 1/2 Study Of Sapacitabine And Venetoclax In Relapsed Or Refractory AML Or MDS Patients,2019-07-22 07:23:00-04:00,CYCCP,positive
328133.0,Cyclacel Pharma Give an Updated From Phase 1 Data,2019-04-01 07:05:00-04:00,CYCCP,neutral
328134.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,CYCCP,negative
328135.0,"Stocks Which Set New 52-Week Low Friday, September 21st",2018-09-24 09:48:00-04:00,CYCCP,negative
328136.0,Cyclacel Reports Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting,2018-04-16 07:06:00-04:00,CYCCP,negative
328137.0,"Cyclacel Announces Presentation of Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias, Lymphomas",2015-09-17 07:04:00-04:00,CYCCP,negative
328138.0,"Cyclacel Announces First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease,",2015-07-02 07:04:00-04:00,CYCCP,negative
328139.0,"Cyclacel & ManRos Therapeutics Reports Licensing, Supply Agreement Regarding Development of Seliciclib in Cystic Fibrosis",2015-06-29 07:00:00-04:00,CYCCP,positive
328140.0,"Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Different Anti-Cancer Compounds",2015-04-20 07:01:00-04:00,CYCCP,negative
328141.0,Cyclacel Pharmaceuticals Prices 10M Share Offering at $1.00/Share,2015-03-04 06:04:00-05:00,CYCCP,positive
328142.0,"Cyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis",2014-12-16 07:19:00-05:00,CYCCP,positive
328143.0,Cyclacel Announces Data Safety Monitoring Board Recommends Continuation of Seamless Phase 3 Trial of Sapacitabine in AML ,2014-10-09 07:02:00-04:00,CYCCP,positive
328144.0,Cyclacel Pharma Reports CYC065 CDK Inhibitor Shows Terapeutic Potential in Acute Leukemias with MLL Rearrangements,2014-09-18 07:02:00-04:00,CYCCP,negative
328145.0,"Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering",2014-04-09 16:06:00-04:00,CYCCP,neutral
328146.0,Cyclacel Reports Positive Phase 2 Data of Sapacitabine for MDS at ASH ,2013-12-09 07:07:00-05:00,CYCCP,positive
328147.0,Cyclacel Pharma Announces Data Safety Monitoring Board Recommends Continuation of SEAMLESS Study of Sapacitabine in AML,2013-11-25 07:18:00-05:00,CYCCP,positive
328148.0,Cyclacel's Seliciclib to be Evaluated for RA,2013-08-12 16:01:00-04:00,CYCCP,neutral
328149.0,Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock,2013-05-15 16:01:00-04:00,CYCCP,neutral
328150.0,"Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene, Dismissal of All Claims in Their Patent Litigation",2013-04-04 07:13:00-04:00,CYCCP,negative
328151.0,Cyclacel Announces Sale of Four Cyclacel Romidepsin-Related Patents to Celgene for $5.5M,2013-04-04 07:13:00-04:00,CYCCP,neutral
328152.0,Cyclacel Comments on Key Business Objectives for 2013 ,2013-01-07 07:22:00-05:00,CYCCP,neutral
328153.0,Aspire Capital Fund to Purchase Up to $20M of Cyclacel Common Stock for $6.29/Share,2012-12-17 07:29:00-05:00,CYCCP,neutral
328154.0,Cyclacel Pharma to Offer New Sapacitabine Data at ASH on Dec. 9th,2012-12-04 09:12:00-05:00,CYCCP,neutral
328155.0,Cyclacel Receives $1.9M Grant,2012-11-05 07:27:00-05:00,CYCCP,positive
328156.0,Data Shows Cyclacel's Sapacitabine Nearly Doubles Expected Survival of Elderly Patients With MDS ,2012-10-15 07:10:00-04:00,CYCCP,neutral
328157.0,Morning Market Movers,2012-09-20 13:53:00-04:00,CYCCP,neutral
328158.0,Cyclacel Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement ,2012-09-13 07:05:00-04:00,CYCCP,neutral
328159.0,Cyclacel Announces Reverse 1-for-7 Stock Split,2012-08-24 09:16:00-04:00,CYCCP,neutral
328160.0,Cyclacel Provides Update on Clinical Progress With Sapacitabine in Solid Tumors Including Activity in BRCA Mutation-Positive Patients ,2011-12-07 07:02:00-05:00,CYCCP,positive
328161.0,Cyclacel Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock and Warrants,2011-07-07 16:02:00-04:00,CYCCP,neutral
328162.0,Cyclacel Pharmaceuticals Announces Pricing of Underwritten Offering at $1.36/Share,2011-07-01 09:15:00-04:00,CYCCP,neutral
328163.0,"Morning Market Movers (BLTI, CYDE, MSHL, STRZ)",2011-01-26 10:01:00-05:00,CYCCP,neutral
328164.0,Cyclacel Completes Previously Announced Private Placement,2010-10-07 16:18:00-04:00,CYCCP,neutral
328165.0,Cyclacel Announces Private Placement Financing for Up to $22.1M,2010-10-05 09:19:00-04:00,CYCCP,neutral
